BCLI - BrainStorm Cell Therapeutics GAAP EPS of -$0.27 misses by $0.13
2023-08-14 07:44:30 ET
- BrainStorm Cell Therapeutics press release ( NASDAQ: BCLI ): Q2 GAAP EPS of -$0.27 misses by $0.13 .
- Cash, cash equivalents, and short-term bank deposits were approximately $.75 million as of June 30, 2023, compared to $3.0 million as of December 31, 2022.
For further details see:
BrainStorm Cell Therapeutics GAAP EPS of -$0.27 misses by $0.13